ALLMedicine™ Myelodysplastic Syndromes Center
Research & Reviews 6,235 results
https://doi.org/10.1186/s13256-020-02623-2 10.1016/j.hoc.2015.06.007 10.1002/ajh.23911 10.1097/MPH.0000000000001174 10.2169/internalmedicine.0497-17 10.1007/s12185-010-0661-2 10.1002/cncr.30084 10.1016/j.jaci.2015.12.1314 10.1182/blood-2006-01-030643 10.1001/jama.2011.194 10.1182/blood-2009-12-257253 10.1016/j.ccell.2016.05.008 10.1126/science.aag1381 10.1038/ng.3610 10.1002/iub.1389 10.1182/blood-2016-07-730556
Journal of Medical Case Reports; Sun Y, Blieden C et. al.
Mar 2nd, 2021 - Hemophagocytic lymphohistiocytosis (HLH) is characterized by hyperinflammation and life-threatening cytopenias. Survival is poor, and management is pivotal on rapid identification of the disease. HLH is associated with hematologic malignancies, ho...
https://doi.org/10.1136/jitc-2020-001818
Journal for Immunotherapy of Cancer; Saberian C, Abdel-Wahab N et. al.
Feb 27th, 2021 - Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-versus-h...
https://doi.org/10.3324/haematol.2020.272559
Haematologica Jachiet V, Moulis G et. al.
Feb 25th, 2021 - Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessin...
https://doi.org/10.1080/16078454.2021.1889161
Hematology (Amsterdam, Netherlands); Cheng WY, Satija A et. al.
Feb 25th, 2021 - To evaluate hypomethylating agent (HMA) persistence in patients with myelodysplastic syndromes (MDS), and examine its association with healthcare resource utilization (HRU) and progression to acute myeloid leukemia (AML). A total of 2,400 adults d...
https://doi.org/10.1111/trf.16093
Transfusion Bowen D, Karakantza M
Feb 22nd, 2021 - Thrombocytopenia and platelet transfusion in myelodysplastic syndromes.|2021|Bowen D,Karakantza M,|
Guidelines 31 results
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.
Nov 22nd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|diagnosis,epidemiology,therapy,
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/
May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.
Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.
Jan 3rd, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...
http://www.bloodjournal.org/content/122/17/2943
Malcovati, L.,et al.
Oct 23rd, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit.
Drugs 57 results see all →
Clinicaltrials.gov 6,489 results
https://doi.org/10.1186/s13256-020-02623-2 10.1016/j.hoc.2015.06.007 10.1002/ajh.23911 10.1097/MPH.0000000000001174 10.2169/internalmedicine.0497-17 10.1007/s12185-010-0661-2 10.1002/cncr.30084 10.1016/j.jaci.2015.12.1314 10.1182/blood-2006-01-030643 10.1001/jama.2011.194 10.1182/blood-2009-12-257253 10.1016/j.ccell.2016.05.008 10.1126/science.aag1381 10.1038/ng.3610 10.1002/iub.1389 10.1182/blood-2016-07-730556
Journal of Medical Case Reports; Sun Y, Blieden C et. al.
Mar 2nd, 2021 - Hemophagocytic lymphohistiocytosis (HLH) is characterized by hyperinflammation and life-threatening cytopenias. Survival is poor, and management is pivotal on rapid identification of the disease. HLH is associated with hematologic malignancies, ho...
https://doi.org/10.1136/jitc-2020-001818
Journal for Immunotherapy of Cancer; Saberian C, Abdel-Wahab N et. al.
Feb 27th, 2021 - Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-versus-h...
https://doi.org/10.3324/haematol.2020.272559
Haematologica Jachiet V, Moulis G et. al.
Feb 25th, 2021 - Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessin...
https://doi.org/10.1080/16078454.2021.1889161
Hematology (Amsterdam, Netherlands); Cheng WY, Satija A et. al.
Feb 25th, 2021 - To evaluate hypomethylating agent (HMA) persistence in patients with myelodysplastic syndromes (MDS), and examine its association with healthcare resource utilization (HRU) and progression to acute myeloid leukemia (AML). A total of 2,400 adults d...
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/transplant-may-improve-survival-in-older-patients-with-high-risk-myelodysplastic-syndrome/
Feb 24th, 2021 - Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN 1102), these patients may indeed achieve a...
News 287 results
https://reference.medscape.com/viewarticle/944879
Feb 2nd, 2021 - Guidelines on the diagnosis and treatment of myelodysplastic syndromes were published in November 2020 by the European Society of Medical Oncology.[1] The diagnosis of myelodysplastic syndromes (MDS) is based on the blood count, the marrow aspirat...
https://www.medscape.com/viewarticle/933602
Jul 7th, 2020 - The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The agency's action gives physicians ...
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/
May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).
https://www.medscape.com/viewarticle/928198
Apr 5th, 2020 - The US Food and Drug Administration (FDA) has approved luspatercept (Reblozyl, Bristol-Myers Squibb/Acceleron) for the treatment of anemia in patients with myelodysplastic syndromes (MDS). The green light represents the first treatment advancement...
https://www.medscape.com/viewarticle/923569
Jan 9th, 2020 - (Reuters Health) - Therapy every 3 weeks with the drug luspatercept dramatically reduced the need for blood transfusions in a subset of patients with lower-risk myelodysplastic syndromes (MDS), according to results from the MEDALIST study reported...